Enema Use for Ulcerative Colitis

First-Line Therapy by Disease Location

• For patients with ulcerative proctitis, the American Gastroenterological Association recommends mesalamine suppositories 1 gram once daily as the preferred initial treatment, as suppositories better target the site of inflammation and are better tolerated, with a high strength of evidence 1, 2

Specific Enema Formulations and Dosing

• The American Gastroenterological Association suggests that once remission is achieved, maintenance can be accomplished with twice-weekly enemas or enemas one week per month when using the 4g/day dose, with a moderate strength of evidence 3
• Rectal corticosteroids, such as budesonide or hydrocortisone, are effective alternatives for induction therapy in distal colitis, with a high strength of evidence 1, 2
• Budesonide foam and hydrocortisone foam show comparable efficacy, with 53% vs 52% remission rates, and a moderate strength of evidence 1, 2
• Rectal corticosteroids have not been studied for maintenance of remission and should only be used short-term for induction, with a low strength of evidence 4

Combination Therapy for Refractory Disease

• For patients with inadequate response to standard mesalamine therapy, combining rectal 5-ASA enemas with rectal corticosteroid enemas is superior to either agent alone, with a high strength of evidence 1, 2, 4
• This combination approach should be considered specifically for refractory ulcerative proctosigmoiditis, with a moderate strength of evidence 3

Foam vs. Enema Formulations

• Mesalamine foam and mesalamine enemas demonstrate equivalent efficacy, with no significant difference in remission rates, and a high strength of evidence 2, 4
• Patients prefer foam over enemas due to easier delivery and better retention, with a moderate strength of evidence 2, 4, 3
• Consider foam formulations for patients unable to retain liquid enemas, with a moderate strength of evidence 2, 4

Critical Pitfalls to Avoid

• Assess for proximal constipation with abdominal X-ray, as fecal loading can impair drug delivery and cause treatment failure, with a moderate strength of evidence 5
• Verify medication adherence and proper administration technique before declaring treatment failure, with a moderate strength of evidence 5

Safety Considerations

• Second-generation corticosteroids like budesonide have a very low risk (<1%) of adrenocortical axis suppression compared to conventional corticosteroids, with a high strength of evidence 3
• Short-term topical corticosteroid therapy carries a low risk of systemic corticosteroid side effects, with a moderate strength of evidence 1, 2

Management of Proctitis

Diagnostic Approach

• The European Crohn’s and Colitis Organisation recommends determining the etiology of proctitis through clinical history, physical examination, and appropriate diagnostic tests 6
• For suspected ulcerative proctitis, the European Crohn’s and Colitis Organisation suggests performing endoscopy with biopsy 7
• For suspected infectious proctitis, the Centers for Disease Control and Prevention recommends performing anoscopy and collecting samples for Gram stain of anorectal exudate for polymorphonuclear leukocytes, testing for HSV, N. gonorrhoeae, C. trachomatis, and T. pallidum 8
• The European Crohn’s and Colitis Organisation advises ruling out other potential causes such as irritable bowel syndrome, Crohn's disease, mucosal prolapse, or cancer 6

Management of Ulcerative Proctitis

• The European Crohn’s and Colitis Organisation recommends topical mesalamine 1g suppository once daily as the preferred initial treatment for mild to moderate ulcerative proctitis 7, 9
• The European Crohn’s and Colitis Organisation suggests that suppositories are more appropriate than enemas for proctitis as they better target the site of inflammation and are better tolerated 9
• The European Crohn’s and Colitis Organisation notes that there is no dose response for topical therapy above 1g 5-ASA daily 9
• The European Crohn’s and Colitis Organisation recommends that once-daily topical therapy is as effective as divided doses 9

Management of Infectious Proctitis

• The Centers for Disease Control and Prevention recommends initiating presumptive therapy with ceftriaxone 250mg IM plus doxycycline 100mg twice daily for 7 days for patients with symptoms of acute proctitis who recently practiced receptive anal intercourse 8
• The Centers for Disease Control and Prevention suggests offering presumptive treatment for LGV with doxycycline 100mg twice daily for a total of 3 weeks for MSM with acute proctitis and either a positive rectal chlamydia NAAT or HIV infection 8
• The Centers for Disease Control and Prevention advises instructing patients to abstain from sexual intercourse until they and their partner(s) have been adequately treated 8
• The Centers for Disease Control and Prevention recommends testing all persons with acute proctitis for HIV and syphilis 8

Mesalamine Suppositories for Proctosigmoiditis

Introduction to Mesalamine Suppositories

• The American Gastroenterological Association (AGA) supports using mesalamine suppositories when patients cannot tolerate enemas, even for proctosigmoiditis, as they will at least treat the rectal component of inflammation and are far better tolerated than enemas 10, 11
• Mesalamine suppositories will still provide therapeutic benefit for patients with left-sided ulcerative proctosigmoiditis who cannot tolerate enemas, though they are not the optimal formulation for disease extending beyond the rectum 10, 11

Treatment Approach

• Start with mesalamine suppositories 1g once daily as they will at least treat the rectal component of inflammation and are far better tolerated than enemas 10, 11
• Suppositories are better retained than enemas and have superior patient tolerance, which is critically important for adherence 10, 11
• Do not abandon topical therapy entirely just because enemas are not tolerated—suppositories still provide meaningful local anti-inflammatory effect even if disease extends beyond their optimal reach 10, 11

Disease Extent and Treatment

• For proctosigmoiditis (disease extending beyond the rectum into the sigmoid colon), enemas are preferred because they reach higher into the colon, whereas suppositories primarily treat rectal inflammation 12

Treatment of Ulcerative Proctitis

Diagnostic Approach and Treatment Algorithm

• Anoscopy or sigmoidoscopy with biopsy is used to evaluate the rectum and rule out Crohn's disease, ischemia, radiation injury, or malignancy, as recommended by the European Society of Gastrointestinal Endoscopy 13
• Topical corticosteroids are superior to placebo (RR=2.83, 95% CI 1.62 to 4.92) with moderate-certainty evidence, according to the American Gastroenterological Association 13
• Budesonide 4 mg suppository may be marginally superior to 2 mg dose (RR=0.74, 95% CI 0.57 to 0.96), as suggested by the National Institute for Health and Care Excellence 13
• For severe or refractory ulcerative proctitis, initiate oral corticosteroids (prednisolone or budesonide MMX), as recommended by the American College of Gastroenterology 13
• Consider biologics, topical tacrolimus, or small molecule therapy if corticosteroids are needed repeatedly or for maintenance, according to the Crohn's and Colitis Foundation 13
• Many patients rapidly respond to initial treatment and remain in remission without maintenance therapy, as reported by the European Crohn's and Colitis Organisation 13
• Alternate-night or every-third-night suppository dosing does not substantially reduce remission rates, as found by the American Gastroenterological Association 13
• Rule out concurrent diagnoses such as irritable bowel syndrome, proximal constipation, infection, solitary rectal ulcer, Crohn's colitis, psoriatic colitis, chemical colitis, or rectal prolapse, as recommended by the World Gastroenterology Organisation 13
• Consider endoscopic re-evaluation to rule out proximal extension of disease if symptoms persist, as suggested by the European Society of Gastrointestinal Endoscopy 13
• Topical corticosteroids show no difference in significant adverse events compared with placebo in pooled data from five studies, as reported by the Cochrane Collaboration 13